The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ
- PMID: 18665169
- PMCID: PMC2527835
- DOI: 10.1038/sj.bjc.6604524
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ
Abstract
Approximately 1 in every 600 women attending breast-screening programmes in the United Kingdom is diagnosed with breast carcinoma in situ (BCIS). However, there is little information on the occurrence of subsequent cancers (other than second breast cancers) in these women. We investigated the occurrence of invasive cancers in 12,836 women diagnosed with BCIS in southeast England between 1971 and 2003, using data from the Thames Cancer Registry. A greater than expected number of subsequent cancers was found for two sites: breast (standardised incidence ratio (SIR) 1.96; 95% confidence interval (CI) 1.79-2.14) and corpus uteri (SIR 1.42; 95% CI 1.11-1.78). For subsequent ipsilateral breast cancer in those treated with breast conservation, the excess was independent of the time since diagnosis of BCIS, whereas for subsequent contralateral breast cancer, there was a steady decline in excess over time. For subsequent uterine cancer, the excess became statistically significant only at >5 years after BCIS diagnosis, consistent with a treatment effect. This was further supported by Cox regression analysis: the risk of subsequent uterine cancer was significantly increased in women receiving hormonal therapy compared with those not receiving it, with a hazard ratio of 2.97 (95% CI 1.84-4.80).
Similar articles
-
Second cancers following in situ carcinoma of the breast.Int J Cancer. 1998 Jul 29;77(3):392-5. doi: 10.1002/(sici)1097-0215(19980729)77:3<392::aid-ijc14>3.0.co;2-a. Int J Cancer. 1998. PMID: 9663601
-
Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ.Ann Surg Oncol. 2017 Sep;24(9):2509-2517. doi: 10.1245/s10434-017-5867-6. Epub 2017 Apr 28. Ann Surg Oncol. 2017. PMID: 28455673
-
Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.Cancer. 2006 May 15;106(10):2104-12. doi: 10.1002/cncr.21864. Cancer. 2006. PMID: 16604564
-
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry.Breast. 2003 Dec;12(6):451-6. doi: 10.1016/s0960-9776(03)00152-8. Breast. 2003. PMID: 14659121 Review.
-
Breast cancer: a review of the literature.J Insur Med. 2003;35(2):85-101. J Insur Med. 2003. PMID: 14733031 Review.
Cited by
-
Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers.Breast Cancer Res Treat. 2017 Nov;166(1):299-306. doi: 10.1007/s10549-017-4410-6. Epub 2017 Jul 25. Breast Cancer Res Treat. 2017. PMID: 28744752 Free PMC article.
-
Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.Medicine (Baltimore). 2015 Aug;94(32):e1359. doi: 10.1097/MD.0000000000001359. Medicine (Baltimore). 2015. PMID: 26266392 Free PMC article.
-
The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden.Breast Cancer Res. 2016 Oct 18;18(1):105. doi: 10.1186/s13058-016-0764-7. Breast Cancer Res. 2016. PMID: 27756431 Free PMC article.
-
'Second primary breast cancers following an initial diagnosis of cancer in one breast: a methodological issue'.Br J Cancer. 2008 Nov 18;99(10):1754-5. doi: 10.1038/sj.bjc.6604718. Epub 2008 Oct 14. Br J Cancer. 2008. PMID: 18854837 Free PMC article. No abstract available.
-
Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?Springerplus. 2014 Aug 5;3:405. doi: 10.1186/2193-1801-3-405. eCollection 2014. Springerplus. 2014. PMID: 25133091 Free PMC article.
References
-
- Andersson M, Storm HH, Mouridsen HT (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013–1017 - PubMed
-
- Atlante G, Pozzi M, Vincenzoni C, Vocaturo G (1990) Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37: 378–380 - PubMed
-
- Bijker N, Meijnen P, Peterse JL, Bogaerts J, van Hoorebeeck I, Julien J-P, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer Randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24: 3381–3387 - PubMed
-
- Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23: 5534–5541 - PubMed
-
- Claus EB, Stowe M, Carter D, Holford T (2003) The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast 12: 451–456 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical